Study S002212

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT04255433
Acronym: SURPASS-CVOT
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 13299
Start: 2020-05-29
Primary completion: 2025-06-12
Lead sponsor: Eli Lilly and Company
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:Tirzepatide; DRUG:Dulaglutide
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:I8F-MC-GPGN; EUDRACT_NUMBER:2019-002735-28; CTIS:2023-507846-96-00; NIH:2023; NIH:2019

Registered primary outcomes

Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] [From randomization (week 0) up to week 259]

Linked records (13)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0006080	Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial. Nissen SE, JAMA cardiology	2026	Randomized trial	PMID 41903177 DOI	cites ClinicalTrials.gov:NCT04255433; registry reference DERIVED:41903177
R0004439	Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration. Khawaji A, Journal of obesity	2025	Systematic review	PMID 40746703 DOI	cites ClinicalTrials.gov:NCT04255433; registry reference DERIVED:40746703
R0009202	Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. Nicholls SJ, The New England journal of medicine	2025	Randomized trial	PMID 41406444 DOI	cites ClinicalTrials.gov:NCT04255433; registry reference DERIVED:41406444
R0016508	Cardioprotective effects of a 'twincretin' drug tirzepatide in heart failure following myocardial infarction. Shang R, Cardiovascular research	2025	Other trial	PMID 39902650 DOI	cites ClinicalTrials.gov:NCT04255433
R0020412	Improvements in post-challenge lipid response following tirzepatide treatment in patients with type 2 diabetes. Mather KJ, Diabetes, obesity & metabolism	2024	Randomized trial	PMID 37989596 DOI	cites ClinicalTrials.gov:NCT04255433
R0036245	Recent Developments in Tirzepatide's Role in Reducing Cardiovascular Disease Risk Factors in Adults with Type 2 Diabetes Jones, Talaya, NSUWorks (Nova Southeastern University)	2024	Other trial		cites ClinicalTrials.gov:NCT04255433
R0007476	Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection. Michos ED, American journal of preventive cardiology	2023	Other trial	PMID 37313358 DOI	cites ClinicalTrials.gov:NCT04255433
R0016833	Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes. Kaneko S, TouchREVIEWS in endocrinology	2022	Other trial	PMID 35949358 DOI	cites ClinicalTrials.gov:NCT04255433; registry reference DERIVED:35949358
R0052144	META-ANALYSIS OF THE EFFECT OF DUAL GIP AND GLP-1 RECEPTOR AGONISTS ON BLOOD PRESSURE LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS Dimitrios Patoulias, Journal of Hypertension	2022	Systematic review	DOI	cites ClinicalTrials.gov:NCT04255433
R0014308	Is tirzepatide in the surpass lane over GLP-1 receptor agonists for the treatment of diabetes? Paneni F, European heart journal	2021	Randomized trial	PMID 34724707 DOI	cites ClinicalTrials.gov:NCT04255433
R0050069	Abstract 13426: The Dual GIP/GLP-1 Receptor Agonist Tirzepatide Improves Cardiovascular Risk Protein Biomarkers in Patients With Type 2 Diabetes Jonathan Matthew Wilson, Circulation	2020	Randomized trial	DOI	cites ClinicalTrials.gov:NCT04255433
R0043692	Fetal origin of vascular aging Shailesh Pitale, Indian Journal of Endocrinology and Metabolism	2011	Randomized trial	PMID 22145131 DOI	cites ClinicalTrials.gov:NCT04255433
R0045813	Imaging of the pituitary: Recent advances Vikas Chaudhary, Indian Journal of Endocrinology and Metabolism	2011	Randomized trial	PMID 22029027 DOI	cites ClinicalTrials.gov:NCT04255433